Bortezomib Injection

DRUG10 trials

Sponsors

pharmaand GmbH, Stichting European Myeloma Network, H. Lee Moffitt Cancer Center and Research Institute, Chinese University of Hong Kong, AHS Cancer Control Alberta

Conditions

Acute Lymphoblastic Leukemia, in RelapseAutologous Stem Cell TransplantLight Chain (AL) Amyloidosis, Stage 3BMultiple MyelomaMyelomaMyeloma MultipleNewly Diagnosed Multiple Myeloma (NDMM)Pancreas Cancer

Phase 1

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

RecruitingNCT06572813

Zhejiang UniversityPancreas Cancer

Start: 2024-11-15End: 2028-03-31Target: 63Updated: 2025-01-10

Phase 2

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

CompletedNCT02654990

pharmaand GmbHMultiple Myeloma

Start: 2016-04-27End: 2022-08-15Updated: 2024-07-12

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

CompletedNCT04131309

Stichting European Myeloma NetworkLight Chain (AL) Amyloidosis, Stage 3B

Start: 2019-09-23End: 2025-01-27Updated: 2025-04-16

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Active, not recruitingNCT04151667

H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma

Start: 2019-11-22End: 2026-05-07Updated: 2026-03-11

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

CompletedNCT04224571

Chinese University of Hong KongAcute Lymphoblastic Leukemia, in Relapse

Start: 2018-09-14End: 2023-02-15Updated: 2023-08-30

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

RecruitingNCT04268199

AHS Cancer Control AlbertaMyeloma, Myeloma Multiple

Start: 2020-05-29End: 2026-12-31Target: 100Updated: 2025-12-15

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Active, not recruitingNCT04653246

Jacob Laubach, MDAutologous Stem Cell Transplant, Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)

Start: 2021-07-13End: 2029-01-13Target: 52Updated: 2025-12-23

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruitingNCT04717700

Ida Bruun KristensenMultiple Myeloma

Start: 2021-08-18End: 2029-06-01Target: 50Updated: 2025-03-18

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

RecruitingNCT05248633

Peking Union Medical College HospitalSolitary Plasmacytoma

Start: 2022-04-21End: 2026-10-31Target: 220Updated: 2024-06-05

Phase 4

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Peking Union Medical College HospitalThrombotic Thrombocytopenic Purpura, Acquired

Start: 2021-12-01End: 2025-11-30Target: 30Updated: 2021-11-26

Related Papers

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Blood2025-09-222 citations

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Blood2024-11-054 citations

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Blood2024-11-051 citations

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Blood2023-11-0210 citations

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Blood2023-11-02

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.

2022-12-0112 citations

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Blood2022-11-157 citations

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis

JACC CardioOncology2022-11-0121 citations

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

HemaSphere2022-06-015 citations

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Blood2021-11-05

Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.

2021-02-034 citations

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

2020-12-0742 citations

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Blood2020-11-054 citations